TransMedics Group (NASDAQ:TMDX) Given New $166.00 Price Target at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX) had its price target increased by equities researchers at Needham & Company LLC from $148.00 to $166.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 21.60% from the stock’s previous close.

Several other research firms have also recently weighed in on TMDX. Piper Sandler decreased their price target on TransMedics Group from $145.00 to $140.00 and set an “overweight” rating for the company in a research note on Thursday, October 30th. Stifel Nicolaus initiated coverage on TransMedics Group in a research report on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price for the company. Jefferies Financial Group began coverage on shares of TransMedics Group in a research note on Monday, October 13th. They set a “buy” rating and a $145.00 target price on the stock. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price target for the company. Finally, Zacks Research cut shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $134.80.

TransMedics Group Stock Performance

TransMedics Group stock opened at $136.51 on Monday. TransMedics Group has a twelve month low of $55.00 and a twelve month high of $156.00. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The company has a market capitalization of $4.66 billion, a P/E ratio of 55.27 and a beta of 2.06. The stock’s 50 day moving average is $125.00 and its 200 day moving average is $122.85.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.29. The firm had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company’s revenue was up 32.2% on a year-over-year basis. During the same period last year, the company earned $0.12 earnings per share. On average, equities research analysts predict that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill sold 5,000 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the transaction, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This represents a 29.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Basile sold 4,142 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the transaction, the director owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. The trade was a 59.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 13,062 shares of company stock worth $1,797,634. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently made changes to their positions in the business. Intech Investment Management LLC raised its position in TransMedics Group by 28.9% during the 2nd quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock valued at $4,608,000 after purchasing an additional 7,713 shares in the last quarter. Valmark Advisers Inc. increased its stake in shares of TransMedics Group by 34.6% during the second quarter. Valmark Advisers Inc. now owns 9,709 shares of the company’s stock valued at $1,301,000 after buying an additional 2,496 shares during the period. Raymond James Financial Inc. raised its holdings in shares of TransMedics Group by 135.8% in the first quarter. Raymond James Financial Inc. now owns 145,393 shares of the company’s stock valued at $9,782,000 after acquiring an additional 83,722 shares in the last quarter. Intrust Bank NA purchased a new stake in TransMedics Group in the second quarter worth about $747,000. Finally, Northern Trust Corp lifted its stake in TransMedics Group by 2.1% in the first quarter. Northern Trust Corp now owns 361,963 shares of the company’s stock worth $24,353,000 after acquiring an additional 7,341 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.